InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,728.80
(
0.41%
)
US TECH 100
19,534.80
(
0.93%
)
Dow Jones
42,052.19
(
0.69%
)
Brent Oil
72.91
(
0.00%
)
Bitcoin
69,660.01
(
0.26%
)
Post# of 253509
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 839
Posts 120657
Boards Moderated 13
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 150791

Friday, 10/19/2012 4:51:10 PM

Friday, October 19, 2012 4:51:10 PM

Post# of 253509
ABT -4.5% on the week despite the blowout results reported in HCV. The Bardoxalone termination (#msg-80651463) and ABT’s noncommittal comments about 2013 did the trick.

2012 non-GAAP EPS guidance was narrowed from the old range of $5.00-5.10 to the new range of $5.06-5.08, implying 4Q12 non-GAAP EPS of $1.50-1.52.

The AbbVie spinoff will trade with the ticker ABBV following the separation from ABT on 12/31/12.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up